



## Financial Tear Sheet

### CORPORATE PROFILE

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

### PRIMARY IR CONTACT


**RussoPartners/LLC**  
 Alex Fudukidis  
 Phone: (646) 942-5632  
 E-mail: [alex.fudukidis@russopartnersllc.com](mailto:alex.fudukidis@russopartnersllc.com)

### STOCK PERFORMANCE

#### ONS (Share)

Exchange	NASDAQ (US Dollar)
Price	\$1.37
Change (%)	▲ 0.03 (2.24%)
Volume	11,377
Today's Open	\$1.29
Previous Close	\$1.34
Intraday High	\$1.38
Intraday Low	\$1.26
52 Week High	\$5.49
52 Week Low	\$1.13

Data as of 05/26/17 3:59 p.m. ET



## LATEST NEWS

May 09, 2017

[Oncobiologics To Present At The World Biosimilar Congress 2017](#)

---

April 17, 2017

[Oncobiologics Secures Additional Funding](#)

---

February 06, 2017

[Oncobiologics Announces Term Extension Of Series A Warrants](#)

---

## UPCOMING EVENTS

There are currently no events scheduled.

## SEC FILINGS

**Filing Date**

**Form**

---

05/16/17

424B3

---

05/16/17

424B3

---

05/16/17

424B3

---

05/16/17

424B3

---

Data provided by Nasdaq. Minimum 15 minutes delayed.